Attention Deficit Hyperactivity Disorder
Conditions
Brief summary
The primary purpose of this study is to evaluate the tolerability and effectiveness of atomoxetine in the treatment of attention problems, hyperactivity, and impulsivity in children with ASD, and secondarily, to evaluate the possible response to atomoxetine on the core symptoms of ASD
Interventions
DRUGAtomoxetine Hydrochloride
Sponsors
Eli Lilly and Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Male and female outpatients between the ages of at least 6 years of age and not more than 17 years of age at visit 1 * Autistic Spectrum Disorder (DSM-IV TR) diagnosis of Autistic disorder or Asperger syndrome or PDDNOS * Clinically significant symptoms of ADHD (i.e. inattention, impulsiveness, and hyperactivity) that have been present for at least six months (for subjects older than 8 years, the onset of symptoms must be before the age of 7 years) * Medication-free for at least two weeks for all psychotropic medications (four weeks for fluoxetine or depot-neuroleptics) * Patients must also be able to swallow capsules
Exclusion criteria
* Patients who weigh less than 20 kg or greater than 60 kg at visit 2 * DSM-IV TR diagnosis of a Pervasive Developmental Disorder other than Autistic Disorder, PDD-NOS, Asperger's Disorder (e.g. Rett's Disorder, Childhood Disintegrative Disorder) * Patients who have a history of Bipolar I or II disorder, schizophrenia, psychosis * Patients who have a current diagnosis of Major Depression (with or without psychotic features), PTSD * Patients with a history of any seizure disorder (other than febrile seizures) or patients who have taken (or are currently taking) anticonvulsants for seizure control
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Test whether atomoxetine is effective in reducing symptoms of inattention and overactivity/impulsivity as measured by the AHDHRS-IV-Parent:Inv scale in pediatric outpatients with ASD accompanied by ADHD behavior problems | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess whether atomoxetine will be effective for improving social functioning and personal sufficiency in children and adolescents with ASD+ADHD | — |
| To assess whether atomoxetine has a positive or negative effect on frequently associated symptoms as impulsive aggression, agitation, self-injurious behavior, troublesome repetitive behavior and poor motor coordination | — |
| To assess whether atomoxetine will be effective in reducing symptoms of inattention and overactivity/impulsivity | — |
| To assess the overall influence on functioning and burden on the family | — |
| To monitor clinical safety and side effects as assessed by adverse events elicited during open-ended questioning | — |
| To assess whether atomoxetine has a positive or negative effect on neuropsychological functioning | — |
Countries
Netherlands
Outcome results
None listed